---
title: Intermittent Erector Spinae Plane Block Via Subcutaneous Port for Cancer Pain
nct_id: NCT07396558
overall_status: NOT_YET_RECRUITING
phase: NA
sponsor: Hanoi Medical University
study_type: INTERVENTIONAL
primary_condition: Cancer Pain
countries: Vietnam
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07396558.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07396558"
ct_last_update_post_date: 2026-02-09
last_seen_at: "2026-05-12T07:31:59.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Intermittent Erector Spinae Plane Block Via Subcutaneous Port for Cancer Pain

**Official Title:** Efficacy of Intermittent Erector Spinae Plane Block Via Subcutaneous Port for Cancer-Related Pain in Patients With Lung Cancer

**NCT ID:** [NCT07396558](https://clinicaltrials.gov/study/NCT07396558)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 180
- **Lead Sponsor:** Hanoi Medical University
- **Conditions:** Cancer Pain, Erector Spinae Plane Block
- **Start Date:** 2026-03-01
- **Completion Date:** 2027-12-31
- **CT.gov Last Update:** 2026-02-09

## Brief Summary

Cancer-related pain is a common and challenging problem in patients with lung cancer, often requiring long-term pain management. Conventional pain treatments, including systemic medications, may not provide adequate relief or may cause significant side effects.

The erector spinae plane (ESP) block is a regional anesthesia technique that can help reduce pain by delivering local anesthetic near the nerves supplying the chest wall. This study aims to evaluate the effectiveness and safety of intermittent ESP block administered through a subcutaneous port for controlling cancer-related pain in patients with lung cancer.

Eligible patients with lung cancer and moderate to severe pain will receive intermittent ESP block injections via a subcutaneous port as part of their pain management plan. Pain intensity, analgesic requirements, and potential side effects will be assessed over time.

The results of this study may help determine whether intermittent ESP block via a subcutaneous port is a useful and feasible option for improving pain control and quality of life in patients with lung cancer.

## Detailed Description

Cancer-related pain in patients with lung cancer is often multifactorial and may be difficult to control using conventional systemic analgesic therapies alone. Regional anesthesia techniques have increasingly been explored as adjunctive approaches to improve pain control while minimizing systemic opioid exposure.

The erector spinae plane (ESP) block is a fascial plane block in which local anesthetic is injected adjacent to the erector spinae muscle, allowing spread to the dorsal and ventral rami of spinal nerves. This technique has been reported to provide effective analgesia for thoracic and chest wall pain with a favorable safety profile.

In this study, patients with lung cancer experiencing moderate to severe cancer-related pain will receive intermittent ESP block administered through a subcutaneous port. The port system allows repeated administration of local anesthetic without the need for repeated needle insertion, potentially improving patient comfort and feasibility of long-term pain management.

Pain intensity will be assessed using standardized pain assessment tools at predefined time points. Additional outcomes include changes in analgesic medication requirements, patient-reported comfort, and the occurrence of procedure-related or treatment-related adverse events.

This study is designed to evaluate the feasibility, effectiveness, and safety of intermittent ESP block via a subcutaneous port as part of a multimodal pain management strategy in patients with lung cancer.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria

* Adult patients diagnosed with advanced-stage lung cancer who are currently receiving palliative care only.
* Presence of chronic cancer-related chest pain lasting longer than 1 month, localized to the thoracic region due to chest wall invasion, pleural involvement, or bone metastases.
* Performance status ≤ 3 according to the Eastern Cooperative Oncology Group (ECOG), allowing placement of a subcutaneous port and maintenance of local anesthetic administration.
* Inadequate pain control with conventional analgesic therapies or clinical indication for the addition of regional analgesia.
* Ability to understand the study procedures and provide written informed consent after receiving a full explanation of the intervention.

Exclusion Criteria:

* Chest pain with radiation to the upper extremities, neck, or shoulder, suggestive of non-localized thoracic pain.
* Severe hepatic or renal dysfunction, or severe heart failure (New York Heart Association class III-IV).
* Local infection at the injection or port placement site, or uncontrolled systemic infection.
* Severe cachexia or insufficient subcutaneous tissue that does not allow safe coverage of the subcutaneous port.
* Known allergy to amide-type local anesthetics or other contraindications to regional anesthesia.
* Severe cognitive impairment, altered consciousness, or inability to cooperate with post-intervention monitoring.
* Lack of adequate caregiver support for home-based follow-up after discharge or inability to coordinate follow-up with local healthcare facilities.
* Severe coagulation disorders, defined as:

  * International normalized ratio (INR) \> 1.5
  * Activated partial thromboplastin time (aPTT) \> 40 seconds
  * Fibrinogen \< 1.5 g/L
  * Platelet count \< 50 × 10⁹/L.
```

## Arms

- **ESP Block Group** (EXPERIMENTAL) — Patients receive intermittent erector spinae plane block administered via a subcutaneous port as part of multimodal pain management for cancer-related pain.
- **Historical Control Group** (NO_INTERVENTION) — Historical control group consisting of patients with lung cancer who previously received standard pain management without erector spinae plane block.

## Interventions

- **Erector Spinae Plane Block** (PROCEDURE) — Intermittent erector spinae plane block administered via a subcutaneous port, allowing repeated delivery of local anesthetic for the management of cancer-related pain in patients with lung cancer.

## Primary Outcomes

- **Change in Pain Intensity Measured by Visual Analog Scale (VAS) at Home at 3 Months After Discharge** _(time frame: From hospital discharge to 3 months after discharge)_ — Pain intensity is assessed at rest and during movement using a 10-cm Visual Analog Scale (VAS), where 0 represents no pain and 10 represents the worst imaginable pain. Assessments are performed at predefined home-based follow-up time points after hospital discharge.

The primary outcome is the change in VAS pain score from hospital discharge to 3 months after discharge, reflecting the sustained effectiveness of intermittent erector spinae plane block in home-based palliative care. Outcomes in the intervention group will be compared with those of the historical control group.

## Secondary Outcomes

- **Change in Pain Intensity at Early Time Points After Intervention** _(time frame: From baseline (H0) to 30 minutes after intervention (H1) and at the time of transfer to the ward (H2))_
- **Pain Intensity Trajectory During Home-Based Follow-Up** _(time frame: Pain intensity at rest and during movement is measured using the Visual Analog Scale (VAS) at predefined home-based follow-up time points up to 3 months after discharge to describe the trajectory of pain control during home-based palliative care.)_
- **Morphine Consumption During Home-Based Palliative Care** _(time frame: At predefined home-based follow-up time points on days 1, 3, and 5; weeks 1, 2, and 3; and months 1, 2, and 3 after hospital discharge)_
- **Procedure-Related and Treatment-Related Adverse Events** _(time frame: At predefined home-based follow-up time points on days 1, 3, and 5; weeks 1, 2, and 3; and months 1, 2, and 3 after hospital discharge)_

## Locations (1)

- Hanoi Medical University, Hanoi, Vietnam

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.hanoi medical university|hanoi||vietnam` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07396558.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07396558*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*